Sanara MedTech posted strong Q3 2025 results, highlighted by significant revenue growth and improved profitability driven by soft tissue repair product sales.

Sanara MedTech's Q2 2025 performance showed notable revenue growth and gross margin improvement, supported by robust product demand in the surgical segment. Despite ongoing investments in the THP segment, losses narrowed compared to the prior year.

Sanara MedTech delivered 26% year-over-year revenue growth in Q1 2025, driven primarily by strong sales of soft tissue repair products. However, the company reported a wider net loss due to increased investments in its Tissue Health Plus segment and corporate infrastructure expansion.

Sanara MedTech achieved net revenue of $26.3 million in Q4 2024, representing a 49% increase compared to the prior year. Gross profit rose to $24.1 million with a strong margin of 91%. Despite these gains, the company recorded a net loss of $1.7 million, influenced by higher SG&A and R&D costs, as well as increased interest expenses.

Sanara MedTech reported a 35% increase in net revenue to $21.7 million for Q3 2024, marking the twelfth consecutive record net revenue quarter. However, the company experienced a net loss of $2.9 million, primarily due to increased SG&A costs related to the Tissue Health Plus (THP) platform buildout, higher interest expense, and an increase in expense due to change in fair value of earnout liabilities.

Sanara MedTech reported a record revenue quarter with a 28% increase compared to the previous year, driven by increased sales of soft tissue repair products and market penetration. However, the company experienced a net loss due to increased SG&A costs, executive separation costs, acquisition costs, and higher amortization expenses.

Sanara MedTech Inc. announced its Q1 2024 results, achieving a record revenue quarter with $18.5 million in net revenue, a 19% increase year-over-year. However, the company reported a net loss of $1.8 million, compared to a net loss of $1.2 million in the same quarter of the previous year.

Sanara MedTech Inc. reported increased net revenues driven by sales growth across all major product lines. The company continues to hire experienced sales managers to drive growth in new territories and expand product sales in existing accounts.

Sanara MedTech Inc. reported a 23% increase in net revenue for the third quarter of 2023, reaching $16.0 million compared to $13.0 million in the same period of the prior year. The company's net loss decreased to $1.1 million from $1.5 million year-over-year. They also completed the acquisition of certain assets related to their collagen business.

Sanara MedTech Inc. announced its second quarter 2023 results, highlighted by record revenue of $15.8 million, a 63% increase compared to the prior year period. The company reported a net loss of $1.9 million, compared to net income of $0.8 million for the three months ended June 30, 2022. Subsequent to the quarter, Sanara completed the acquisition of certain assets related to its collagen products business.

Sanara MedTech Inc. announced record revenue for the first quarter of 2023, with March being the highest sales month in the company's history. The growth was driven by an increased number of facilities selling their products, higher average sales per facility, and the promotion of expanded product lines. The company also submitted its Precision Healing Multispectral Imager for 510(k) clearance and received 510(k) clearance for BIASURGE™ Advanced Surgical Solution, with commercial launch preparation underway for late 2023.

Sanara MedTech Inc. reported record sales results in both the fourth quarter and the full year, driven by the expansion of its sales team's geographic coverage, increased average sales per facility, and an expanded product line.

Sanara MedTech Inc. announced its third quarter 2022 results, highlighting a record revenue achievement driven by increased product recognition. The company is integrating Scendia Biologics and has formed a new chronic wound care partnership with InfuSystem Holdings, Inc.

Sanara MedTech reported record revenue in Q2 2022, marking the first quarter with over $3 million in sales each month. The company also completed the acquisition of Scendia Biologics, LLC.

Sanara MedTech announced its Q1 2022 results, highlighting record revenue and the completion of the Precision Healing acquisition.

Sanara MedTech reported record sales results in both the fourth quarter and the full year, building on the success of their Cellerate product line and executing their strategy to offer a comprehensive solution for wound and skin care in all care settings.

Sanara MedTech reported a 35% increase in revenue compared to the same quarter last year, despite the impact of the COVID-19 Delta variant on elective procedures. The company experienced a higher net loss due to increased SG&A expenses related to sales force expansion and the addition of Rochal Industries, LLC.

Sanara MedTech reported a record sales quarter driven by strong product sales across a wider number of facilities and geographies. The company closed on the Pixalere partnership and completed the acquisition of certain assets of Rochal Industries, LLC.